PMID- 16405756
OWN - NLM
STAT- MEDLINE
DCOM- 20060829
LR  - 20150313
VI  - 25
IP  - 1
DP  - 2006 Jan
TI  - [Treatment and prognosis of stage III-IV laryngeal squamous cell carcinoma].
PG  - 80-4
AB  - BACKGROUND & OBJECTIVE: Laryngeal squamous cell carcinoma (LSCC) is a common 
      malignancy of the head and neck. Stage I-II LSCC patients have a favorable 
      prognosis after operation or radiotherapy, but the curative effect and prognosis 
      of stage III-IV LSCC are not satisfying, and its treatment is also controversial. 
      This study was to summarize our experience in treating stage III-IV LSCC 
      patients, evaluate the treatment results, and seek more reasonable therapeutic 
      modality. METHODS: Records of 202 stage III-IV LSCC patients, treated in Cancer 
      Center of Sun Yat-sen University from Jan. 1, 1991 to Jan. 1, 2000, were 
      retrospectively analyzed. Of the 202 patients, 64 received surgery alone, 83 
      received surgery and preoperative or postoperative radiotherapy, 41 received 
      radiotherapy, and 14 received chemotherapy. The overall survival rate was 
      estimated using life table method by SPSS10.0 software. Survival curves were 
      compared with Wilcoxon method; relapse statuses were compared with Chi(2) test. 
      RESULTS: The 5- and 10-year overall survival rates of the 202 patients was 
      (42.12+/-3.62)% and (33.20+/-4.32)%, and the median survival time was 48.5 
      months. The 5-year survival rates were 61.07% in glottic carcinoma group and 
      26.07% in supraglottic carcinoma group, and were 53.41% in surgery alone group, 
      51.04% in surgery plus radiotherapy group, 18.33% in radiotherapy group and 7.14% 
      in chemotherapy group. There was no significant difference between surgery alone 
      group and surgery plus radiotherapy group (P>0.05). Of the 147 patients received 
      surgery, the 5-year survival rates were 56.15% for the 31 patients received 
      partial laryngectomy and 52.08% for the 116 patients received total laryngectomy. 
      Eleven patients had tumor relapsed after total laryngectomy within 5 years. 
      CONCLUSIONS: Surgery, especially total laryngectomy, is the major treatment 
      modality for stage III-IV LSCC. Partial laryngectomy may be performed with strict 
      selection. Postoperative radiotherapy may be preformed on the patients with 
      suspect of tumor residue or positive margin.
FAU - Tian, Wen-Dong
AU  - Tian WD
AD  - State Key Laboratory of Oncology in Southern China, Guangzhou, Guangdong 510060, 
      P. R. China.
FAU - Zeng, Zong-Yuan
AU  - Zeng ZY
FAU - Chen, Fu-Jin
AU  - Chen FJ
FAU - Wu, Guo-Hao
AU  - Wu GH
FAU - Guo, Zhu-Ming
AU  - Guo ZM
FAU - Zhang, Quan
AU  - Zhang Q
LA  - chi
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Ai Zheng
JT  - Ai zheng = Aizheng = Chinese journal of cancer
JID - 9424852
RN  - 11056-06-7 (Bleomycin)
RN  - Q20Q21Q62J (Cisplatin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Bleomycin/administration & dosage
MH  - Carcinoma, Squamous Cell/drug therapy/radiotherapy/*surgery
MH  - Cisplatin/administration & dosage
MH  - Combined Modality Therapy
MH  - Female
MH  - Fluorouracil/administration & dosage
MH  - Follow-Up Studies
MH  - Humans
MH  - Laryngeal Neoplasms/drug therapy/radiotherapy/*surgery
MH  - Laryngectomy/*methods
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2006/01/13 09:00
MHDA- 2006/08/30 09:00
CRDT- 2006/01/13 09:00
PHST- 2006/01/13 09:00 [pubmed]
PHST- 2006/08/30 09:00 [medline]
PHST- 2006/01/13 09:00 [entrez]
AID - 1000467X2006010080 [pii]
PST - ppublish
SO  - Ai Zheng. 2006 Jan;25(1):80-4.